Technological advances in radioimmunotherapy.
Radioimmunotherapy (RIT) is a method of selectively delivering radionuclides with toxic emissions to cancer cells, while reducing the dose to normal tissues. Although primary tumours can often be treated successfully with external beam radiotherapy or surgery, metastases often escape detection and treatment, leading to therapy failure, and these can be treated with systemic targeted therapies such as RIT. This review describes more recent developments in the field, including both technological developments from the laboratory and increasingly encouraging findings from clinical studies.
Dearling
J L J
JL
Cancer Research UK Targeting & Imaging Group, Department of Oncology, University College London (Hampstead Campus), London, UK. j.dearling@hotmail.com
Pedley
R B
RB
D000911:Antibodies, Monoclonal / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000378:metabolism; D000915:Antibody Affinity; D019583:Dose Fractionation, Radiation; D006801:Humans; D007668:Kidney / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology / Q000473:pathology / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000379:methods*; D011868:Radioisotopes / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D011868:Radioisotopes